IP Library Granted Patent US 10,967,104
Granted Patent B2
US 10,967,104 · App. 15/688,256 · Granted Apr 6, 2021

Encapsulated or coated stent systems

Inventors: David B. Masters (Minneapolis, MN); Eric P. Berg (Plymouth, MN)
Assignee: PETVIVO HOLDINGS, INC.
A61L31/10A61F2/90A61F2/91A61L31/043A61L31/16A61F2/0077A61F2/064A61F2/852A61F2002/826A61F2250/0063A61F2250/0067
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,967,104
App. No.
15/688,256
Granted
Apr 6, 2021
Kind
B2
Abstract

A stent system comprising zero or more inner stents inserted into an outer stent. The inner stents and outer stent are separated and/or encapsulated by a protein-based material of a protein matrix and/or a set biocoacervate, each comprising one or more biocompatible proteins and one or more biocompatible solvents. The protein-based material may also include one or more carbohydrates and one or more pharmacologically active agents.

Claims (5)

1. A single strand stent system comprising a single strand twisted to form a loop strut or two or more rounded loops said loop strut or loops coated or encapsulated with a biocoacervate material comprising one or more primary proteins, one or more secondary proteins, one or more proteoglycans, and one or more biocompatible solvents, wherein the biocoacervate material is crosslinked with one or more crosslinking agents, wherein the biocoacervate material comprises a thermoplastic biocoacervate material configured to be remelted and reformed into a desired shape and size prior to being crosslinked with the one or more crosslinking agents.

2. The single strand stent system of claim 1 further comprising one or more pharmacologically active agents.

3. The single strand stent system of claim 2 wherein the one or more pharmacologically active agents is paclitaxel, rapamycin or estradiol.

4. The single strand stent system of claim 1 further comprising a mesh tube coated or encapsulated with the biocoacervate material.

5. The single strand stent system of claim 1 includes the two or more loops and the loops are selected from the group consisting of o-rings, c-rings and oval-rings.

Assignments (2)
MERGER Recorded May 31, 2019
From: GEL-DEL TECHNOLOGIES, INC.
To: PETVIVO HOLDINGS, INC.
Reel/Frame 049336/0741 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2017
From: MASTERS, DAVID B.; BERG, ERIC P.
To: GEL-DEL TECHNOLOGIES, INC.
Reel/Frame 043424/0398 →
Continuity (4)
Continuation 11916165
Continuation 10871946 · Jun 17, 2004
Provisional Application 60478976 · Jun 17, 2003
Related Publication 20180193534A1 · Jul 12, 2018